waiting_room_2Siemens’ PETNET Solutions Inc, a wholly owned subsidiary of Siemens Healthcare, will formulate the VPAC1 molecular biomarker 64Cu TP-3805 exclusively for clinical trials for the biopharmaceutical firm NuView Life Sciences, Inc, of Park City, Utah.

Targeting the VPAC1 receptor over-expressed on the surface of malignant cancer cells, 64Cu TP-3805 is being studied for prostate and breast cancer imaging using positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MR). As a 64Cu-labeled peptide with a longer half-life (12.7 hours), 64Cu TP-3805 is better suited for clinical trial distribution across a large geographical area than other commonly used PET radiopharmaceuticals.

For more information, visit PETNET Solutions or NuView Life Sciences.